Evidence map›Paper›PMID 42638592›Full record

ReviewBioscience reports2026

From metabolic intermediary to neurotransmitter: purinergic signaling in neurophysiology and vulnerability of brain circuits.

Lucas Bonfim Marques, Allan de Carvalho, Raphael Luiz Lobo da Silva Souza, Fernanda Tibolla Viero, Luiz Roberto G Britto, Henning Ulrich

Abstract readReview
In one paragraph

Review in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lucas Bonfim Marques *Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.ORCID 0000-0002-6593-0685
Allan de Carvalho *Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.ORCID 0009-0001-7693-2766
Raphael Luiz Lobo da Silva Souza *Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.ORCID 0000-0002-0900-3609
Fernanda Tibolla VieroDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.
Luiz Roberto G BrittoDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Henning UlrichDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.ORCID 0000-0002-2114-3815

Funding

National Council for Scientific and Technological Development (CNPq) 141580/2023-2National Council for Scientific and Technological Development (CNPq) 150216/2026-2National Council for Scientific and Technological Development (CNPq) 306077/2023-0National Council for Scientific and Technological Development (CNPq) 409156/2024-8Sao Paulo Research Foundation (FAPESP) 2024/06017-7Sao Paulo Research Foundation (FAPESP) 2024/17387-0Sao Paulo Research Foundation (FAPESP) 2025/26861-0
6 · The paper itself

Abstract

Purinergic signaling represents an ancient intercellular communication system. Operating at the interface between bioenergetic metabolism and damage detection, extracellular purines such as adenosine 5'-triphosphate (ATP) and adenosine (ADO) are recruited into the nervous system for neurotransmission and homeostatic control. Here, we discuss how purine-dependent mechanisms modulate excitation-inhibition balance, neuroplasticity, and neurodevelopment. In the hippocampus, ADO exerts inhibitory tonic functions, while ATP is released during high neuronal activity, being considered a destabilizing factor during pathological conditions. In the striatum, purinergic signaling intersects with dopaminergic and glutamatergic pathways in the fine-tuning of motor control, with ADO receptors modulating corticostriatal transmission and influencing vulnerability to excitotoxicity and neurodegeneration. Focusing on the cerebellum, we illustrate how purinergic signaling contributes to neurodevelopment and neuroplasticity, and how dysfunctions of the purinergic signaling system give rise to associated neuropathologies. In the brainstem, we demonstrate how purinergic signaling modulates autonomic and respiratory circuits to maintain cardiorespiratory homeostasis through astrocyte-neuron communication. Despite its adaptive value, purinergic signaling is optimized for transient, activity-, or damage-dependent activation. Thus, we argue that, under contemporary conditions characterized by chronic stress and extended lifespan, the purinergic signaling system may undergo a shift from predominantly acute to chronic engagement. This evolutionary mismatch may promote maladaptive purinergic activity, contributing to its involvement in synaptic dysfunction, neuroinflammation, and selective vulnerability of brain circuits. Moreover, we integrate evolutionary, neurophysiological, and neuropathological perspectives to propose purinergic signaling as a key mechanistic bridge linking neural function, bioenergetic metabolism, molecular pathways, and neurodegenerative diseases.

Indexed as

BrainNeurotransmitter AgentsReceptors, PurinergicAdenosineAdenosine TriphosphateAnimalsEnergy MetabolismHumansNeurodegenerative DiseasesNeurodevelopmentNeuronal PlasticityNeuronsSignal TransductionSynaptic TransmissionAdenosineAdenosine TriphosphateNeurotransmitter AgentsReceptors, Purinergicbrainstemcerebellumepileptic seizurehippocampusHuntington's diseaseneurodegeneration

Identifiers

PMID42638592
PMCPMC13507043

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.